Drugs / RMC-9805
Trials 7
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-08-05 | Revolution Medicines, Inc. | Results Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress revmed.com ↗
Reporting encouraging new combination data in first-line non-small cell lung cancer supporting registrational studies of elironrasib and zoldonrasib |
| 2026-07-02 | Revolution Medicines, Inc. | Results Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026 revmed.com ↗
Zoldonrasib plus daraxonrasib demonstrated a manageable safety and tolerability profile that was broadly consistent with the established profile of daraxonrasib monotherapy. |
| 2026-06-08 | Tango Therapeutics, Inc. | Results Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer tangotx.com ↗ |
| 2026-04-19 | Revolution Medicines, Inc. | Results Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting revmed.com ↗
REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC). |
| 2026-01-08 | Revolution Medicines, Inc. | Regulatory Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib revmed.com ↗ |
| 2025-07-24 | Revolution Medicines, Inc. | Results Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor revmed.com ↗
Data reported in this paper demonstrate that this activity drives deep and durable tumor regressions in preclinical models of multiple tumor types with KRAS G12D mutations. |
| 2025-04-27 | Revolution Medicines, Inc. | Results Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting revmed.com ↗ |
| 2024-10-25 | Revolution Medicines, Inc. | Results Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma revmed.com ↗
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced preliminary safety and antitumor data for RMC-9805, its RAS(ON) G12D-selective inhibitor, in patients with previously treated pancreatic ductal adenocarcinoma (PDAC). |
All press releases naming this drug 11 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RMC-9805 | “Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma” NCT07805954 ↗5“With or Without Zoldonrasib (RMC-9805) as First-line Treatment” NCT07621718 ↗ |
| Known as | zoldonrasib | “This approach yielded orally bioavailable compounds with marked antitumor activity in multiple preclinical models of KRASG12D cancers, including the investigational agent...” PMID 40705880 ↗ Jul 2025 |
| Action | Inhibit | “RMC-9805, a selective and orally bioavailable KRAS G12D(ON) inhibitor” NCT06040541 ↗ |
| Route | Oral | “Oral Tablet” NCT06162221 ↗ |
| Target | KRAS | “RMC-9805, a selective and orally bioavailable KRAS G12D(ON) inhibitor” NCT06040541 ↗ |